News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Invitrogen Corporation (IVGN) Signs Definitive Agreement To Acquire BioSource International, Inc. (BIOI); Deal Strengthens Proteomics Franchise And Positions The Company To Enter New Markets; $130 Million



10/19/2005 5:09:00 PM

CARLSBAD, Calif.--(BUSINESS WIRE)--July 26, 2005--Invitrogen Corporation (Nasdaq:IVGN) today announced the signing of a definitive agreement to acquire publicly held life sciences company BioSource International (Nasdaq:BIOI) in an all-cash transaction totaling approximately $130 million. The transaction is subject to customary closing conditions, including regulatory approval and the approval of BioSource stockholders. The transaction is expected to close by the end of the year. This deal augments Invitrogen's growing collection of protein and primary antibody products gained through its recent acquisitions of Zymed Laboratories and Caltag Laboratories. Additionally, it bolsters Invitrogen's offerings in both kinase and cytokine assay technologies for research applications and provides the company an opportunity to enter new markets in immunology, oncology and neurodegenerative disease.

Read at Reuters
Read at AP
Read at BioSpace.com
Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES